Dexcom Promotes CGM As First-Line Tool In Type 2 Diabetes

Company Combines Education, Advocacy And Clinical Studies To Shift Standard Of Treatment.

 
• By Shubham Singh
  
One of the most significant is the Steno2Tech study, a 12-month, single-center, randomized controlled trial conducted at the Steno Diabetes Center, Copenhagen, Denmark

More from Diabetic Care

More from Medtech Insight